title: [Current therapeutic strategies for mantle cell lymphoma].
abstract: Mantle cell lymphoma is a subtype of B‑cell lymphoma with a mostly aggressive behavior and poor long-term prognosis. The choice of therapy depends on the age, performance status and risk profile of the patient. Randomized trials have confirmed the superiority of a dose-intensified induction therapy containing cytarabine followed by autologous stem cell transplantation in the first-line treatment of younger patients with a good general condition. Elderly patients benefit from a rituximab maintenance therapy after immunochemotherapy. Novel targeted therapies of the B‑cell receptor pathway with the Bruton's tyrosine kinase inhibitor ibrutinib and the mechanistic target of rapamycin (mTOR) antagonist temsirolimus as well as immunomodulatory drugs (lenalidomide) have shown promising results in relapsed disease. The proteasome inhibitor bortezomib has been approved for first-line treatment in combination with conventional chemotherapy.
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland. martin.dreyling@med.uni-muenchen.de.
authors.forename: M
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Schnaiter
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Schmidt
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
authors.forename: E
authors.initials: E
authors.lastname: Hoster
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020522:Lymphoma, Mantle-Cell / Q000473:pathology* / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011878:Radiotherapy / Q000379:methods; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Autologous transplantation; B-cell lymphoma; Immunochemotherapy; Receptor pathways; Targeted therapy